Page 5 - Primary Endpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed

Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced top-line results from the Phase 2 clinical trial of ADX‑629, an investigational new drug administered orally to patients with chronic cough. The company plans to discuss these results with regulatory authorities while considering expanding clinical testing to include patients with frequent coughing and active inflammation. The Phase 2 trial included 51 patients suffering from refractory or unexplained chronic cough that persists for more than eig

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The trial achieved statistical significance for the primary endpoint and all secondary endpoints. Also Read: Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients. Relative to patients treated with vehicle, patients treated with reproxalap reported statistica

Resynchronization therapy jumps forward with 3 new studies that support but push the envelope of a new guideline statement on physiologic pacing for heart failure.

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate